MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer

HOUSTON and MONROVIA, Calif. ? The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer. This collaboration joins Xencor’s innovative XmAb® technology and protein engineering expertise to create bispecific antibodies…

Details

Dartmouth-Hitchcock and West Health bring geriatric telemedicine to rural New England

Lebanon, NH – Dartmouth-Hitchcock Health (D-HH), New Hampshire’s only academic health system serving nearly 2 million patients across northern New England, and West Health, a family of nonprofit and nonpartisan organizations working to lower health care costs to enable successful aging, are bringing accredited geriatric emergency care and, for the first time, providing older adults…

Details

How effective are educational support programs for children with cancer?

As children undergo treatment for cancer, they may miss school and risk falling behind in their education. An analysis published in Pyscho-Oncology has examined the educational support programs provided to children with cancer. The analysis looked at several different peer programs, teacher programs, and school re-entry programs. School re-entry programs appeared to provide a promising…

Details

Hydroxychloroquine blood levels predict clotting risk in patients with lupus

The antimalarial drug hydroxychloroquine is frequently prescribed to treat symptoms of the autoimmune disease lupus. In addition to decreasing disease flares, the drug can also prevent blood clots, which are a major problem in individuals with lupus. A new study in Arthritis & Rheumatology shows that monitoring patients’ blood levels of hydroxychloroquine can predict their…

Details